Pages that link to "Q37263479"
Jump to navigation
Jump to search
The following pages link to The multifaceted roles of the receptor tyrosine kinase ROS in development and cancer (Q37263479):
Displaying 50 items.
- Molecular Subtypes and Personalized Therapy in Metastatic Colorectal Cancer (Q26747329) (← links)
- ALK and ROS1 as targeted therapy paradigms and clinical implications to overcome crizotinib resistance (Q26775347) (← links)
- Targeted therapies in development for non-small cell lung cancer (Q27022852) (← links)
- Comparison of detection methods and follow-up study on the tyrosine kinase inhibitors therapy in non-small cell lung cancer patients with ROS1 fusion rearrangement (Q27311389) (← links)
- Crizotinib in ROS1-rearranged non-small-cell lung cancer. (Q27853075) (← links)
- PF-06463922 is a potent and selective next-generation ROS1/ALK inhibitor capable of blocking crizotinib-resistant ROS1 mutations (Q27853138) (← links)
- Testing for ROS1 in non-small cell lung cancer: a review with recommendations (Q28070062) (← links)
- Regulation of epithelial function, differentiation, and remodeling in the epididymis (Q28081095) (← links)
- Breakpoint analysis of transcriptional and genomic profiles uncovers novel gene fusions spanning multiple human cancer types (Q28486949) (← links)
- Genome-wide association analysis identifies new lung cancer susceptibility loci in never-smoking women in Asia (Q28943345) (← links)
- Survey of tyrosine kinase signaling reveals ROS kinase fusions in human cholangiocarcinoma (Q33799157) (← links)
- Biomarkers That Currently Affect Clinical Practice in Lung Cancer: EGFR, ALK, MET, ROS-1, and KRAS (Q34023414) (← links)
- ROS1 signaling regulates epithelial differentiation in the epididymis (Q34068363) (← links)
- Targeted therapies in non-small cell lung cancer: emerging oncogene targets following the success of epidermal growth factor receptor (Q34158153) (← links)
- Identifying and targeting ROS1 gene fusions in non-small cell lung cancer (Q34295696) (← links)
- Molecular pathways: ROS1 fusion proteins in cancer (Q34347504) (← links)
- Activation of RAS family members confers resistance to ROS1 targeting drugs. (Q34463388) (← links)
- Oxido-reductive regulation of vascular remodeling by receptor tyrosine kinase ROS1. (Q35145481) (← links)
- Activated RET and ROS: two new driver mutations in lung adenocarcinoma (Q35206630) (← links)
- Clinical and pathological significance of ROS1 expression in intrahepatic cholangiocarcinoma (Q35811132) (← links)
- Cytoplasmic c-ros oncogene 1 receptor tyrosine kinase expression may be associated with the development of human oral squamous cell carcinoma (Q35871442) (← links)
- Preclinical rationale for use of the clinically available multitargeted tyrosine kinase inhibitor crizotinib in ROS1-translocated lung cancer. (Q36044531) (← links)
- Biomarkers and targeted systemic therapies in advanced non-small cell lung cancer (Q36260477) (← links)
- Effects of the activated mitogen-activated protein kinase pathway via the c-ros receptor tyrosine kinase on the T47D breast cancer cell line following alcohol exposure (Q36684631) (← links)
- Comparison of gene expression of the oncogenic Wnt/β-catenin signaling pathway components in the mouse and human epididymis (Q36748491) (← links)
- ROS1 expression in invasive ductal carcinoma of the breast related to proliferation activity (Q36793176) (← links)
- Why are epididymal tumours so rare? (Q37037784) (← links)
- Novel targets in non-small cell lung cancer: ROS1 and RET fusions (Q37038500) (← links)
- The oncogenic lung cancer fusion kinase CD74-ROS activates a novel invasiveness pathway through E-Syt1 phosphorylation. (Q37122187) (← links)
- Benefit-Risk Summary of Crizotinib for the Treatment of Patients With ROS1 Alteration-Positive, Metastatic Non-Small Cell Lung Cancer (Q37162291) (← links)
- Mouse model of intrahepatic cholangiocarcinoma validates FIG-ROS as a potent fusion oncogene and therapeutic target (Q37353061) (← links)
- Tyrosine kinase gene rearrangements in epithelial malignancies (Q37515966) (← links)
- Imprecision in the Era of Precision Medicine in Non-Small Cell Lung Cancer (Q37743107) (← links)
- ROS receptor tyrosine kinase: a new potential target for anticancer drugs (Q37777990) (← links)
- New targets in non-small cell lung cancer (Q38114835) (← links)
- Efficacy of crizotinib inhibiting specific molecular pathways in non-small-cell lung carcinoma (Q38386866) (← links)
- Prognostic and predictive biomarkers for targeted therapy in NSCLC: for whom the bell tolls? (Q38584814) (← links)
- Entrectinib: a potent new TRK, ROS1, and ALK inhibitor (Q38604854) (← links)
- Recent Advances in Targeting ROS1 in Lung Cancer (Q38640765) (← links)
- Emerging targeted therapies in non-small cell lung cancer (Q38653045) (← links)
- A decade of GWAS results in lung cancer. (Q38671004) (← links)
- Utilization of ancillary studies in the cytologic diagnosis of respiratory lesions: The papanicolaou society of cytopathology consensus recommendations for respiratory cytology (Q38937135) (← links)
- Downregulation of ROS-FIG inhibits cell proliferation, colony‑formation, cell cycle progression, migration and invasion, while inducing apoptosis in intrahepatic cholangiocarcinoma cells (Q38980941) (← links)
- Comprehensive analysis of RET and ROS1 rearrangement in lung adenocarcinoma (Q39126870) (← links)
- ROS1 rearrangement and response to crizotinib in Stage IV non-small cell lung cancer. (Q41399811) (← links)
- The ortholog of the human proto-oncogene ROS1 is required for epithelial development in C. elegans (Q42032097) (← links)
- Immunohistochemistry for predictive biomarkers in non-small cell lung cancer (Q47140225) (← links)
- Long-term progression-free survival in an advanced lung adenocarcinoma patient harboring EZR-ROS1 rearrangement: a case report (Q49404537) (← links)
- The rationale for druggability of CCDC6-tyrosine kinase fusions in lung cancer. (Q49887888) (← links)
- [Clinical significance of ROS1 rearrangements in non-small cell lung cancer]. (Q54389938) (← links)